Regeneron Pharmaceuticals, Inc.

REGN · NASDAQ

Regeneron reported $14.34 billion of 2025 revenue and $3.61 billion of Q1 2026 revenue. The thesis turns on EYLEA franchise durability, Dupixent economics, pipeline conversion, cash generation and patent/regulatory risk.

Follow Add to Watchlist Ask Question

NASDAQ REGN Coverage Bootstrap Regeneron Pharmaceuticals, Inc.

Latest ReportMay 20, 2026Regeneron: the blockbuster biotech that still has to outrun concentration riskView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.